Response to: Correspondence on 'Current myositis clinical trials and tribulations' by Saygin
et al
Ann Rheum Dis
.
2024 Mar 28:ard-2024-225762.
doi: 10.1136/ard-2024-225762.
Online ahead of print.
Authors
Didem Saygin
1
,
Victoria Werth
2
,
Julie J Paik
3
,
Jin Kyun Park
4
,
Merrilee Needham
5
,
Ingrid E Lundberg
6
,
Lisa Christopher-Stine
7
Affiliations
1
Department of Medicine, Division of Rheumatology, University of Pittsburgh Medical Center, Pittburgh, Pennsylvania, USA didemuzunaslan@gmail.com.
2
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
3
Rheumatology, Johns Hopkins Unveristy, Baltimore, Maryland, USA.
4
Rheumatology, Seoul National University Hospital, Seoul, Korea (the Republic of).
5
Department of Neurology, IIID Murdoch University and University of Notre Dame, Perth, Western Australia, Australia.
6
Rheumatology, Stockholm, Sweden.
7
Medicine/Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
PMID:
38548313
DOI:
10.1136/ard-2024-225762
No abstract available
Keywords:
Dermatomyositis; Outcome Assessment, Health Care; Polymyositis.